{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:19:32Z","timestamp":1787062772414,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13318-022-00802-8","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T23:02:50Z","timestamp":1667343770000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review"],"prefix":"10.1007","volume":"48","author":[{"given":"Navid","family":"Omidkhoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Mahdiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-8634","authenticated-orcid":false,"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","volume":"37","author":"S Bellentani","year":"2017","unstructured":"Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81\u20134.","journal-title":"Liver Int"},{"issue":"5","key":"802_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1053\/bega.2002.0325","volume":"16","author":"M Haque","year":"2002","unstructured":"Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Cl Ga. 2002;16(5):709\u201331.","journal-title":"Best Pract Res Cl Ga"},{"issue":"4","key":"802_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","volume":"141","author":"MR Charlton","year":"2011","unstructured":"Charlton MR, et\u00a0al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141(4):1249\u201353.","journal-title":"Gastroenterology"},{"issue":"1","key":"802_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et\u00a0al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"Suppl 7","key":"802_CR5","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/jcph.671","volume":"56","author":"M Patel","year":"2016","unstructured":"Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol. 2016;56(Suppl 7):S23-39.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"802_CR6","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","volume":"106","author":"N Thakkar","year":"2017","unstructured":"Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharma Sci. 2017;106(9):2282\u201394.","journal-title":"J Pharma Sci"},{"issue":"4","key":"802_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1055\/s-0028-1091981","volume":"28","author":"J Jou","year":"2008","unstructured":"Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28(4):370\u20139.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"802_CR8","doi-asserted-by":"publisher","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","volume":"294","author":"D Greco","year":"2008","unstructured":"Greco D, et\u00a0al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008;294(5):G1281-1287.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"36","key":"802_CR9","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1073\/pnas.0904944106","volume":"106","author":"E Fabbrini","year":"2009","unstructured":"Fabbrini E, et\u00a0al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009;106(36):15430\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"802_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/pr.108.00001","volume":"60","author":"N Anderson","year":"2008","unstructured":"Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev. 2008;60(3):311\u201357.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"802_CR11","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/db07-1383","volume":"57","author":"M Bell","year":"2008","unstructured":"Bell M, et\u00a0al. Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes. 2008;57(8):2037\u201345.","journal-title":"Diabetes"},{"issue":"2","key":"802_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI200422422","volume":"114","author":"JD Browning","year":"2004","unstructured":"Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147\u201352.","journal-title":"J Clin Invest"},{"issue":"5","key":"802_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/gast.2001.23256","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal AJ, et\u00a0al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120(5):1183\u201392.","journal-title":"Gastroenterology"},{"key":"802_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145\u201371.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"802_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1124\/dmd.113.055996","volume":"42","author":"MJ Canet","year":"2014","unstructured":"Canet MJ, et\u00a0al. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos. 2014;42(4):586\u201395.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"802_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.114.220764","volume":"352","author":"AL Dzierlenga","year":"2015","unstructured":"Dzierlenga AL, et\u00a0al. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2015;352(3):462\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"802_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/dmd.111.041095","volume":"40","author":"RN Hardwick","year":"2012","unstructured":"Hardwick RN, et\u00a0al. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos. 2012;40(3):450\u201360.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"802_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, et\u00a0al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"802_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jhep.2008.12.016","volume":"50","author":"F Caballero","year":"2009","unstructured":"Caballero F, et\u00a0al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50(4):789\u201396.","journal-title":"J Hepatol"},{"issue":"12","key":"802_CR20","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1124\/dmd.111.041012","volume":"39","author":"RN Hardwick","year":"2011","unstructured":"Hardwick RN, et\u00a0al. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39(12):2395\u2013402.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"802_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1124\/dmd.114.062703","volume":"43","author":"MJ Canet","year":"2015","unstructured":"Canet MJ, et\u00a0al. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metab Dispos. 2015;43(6):829\u201335.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"802_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/liv.13109","volume":"36","author":"J Vega-Badillo","year":"2016","unstructured":"Vega-Badillo J, et\u00a0al. Hepatic miR-33a\/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects. Liver Int. 2016;36(9):1383\u201391.","journal-title":"Liver Int"},{"issue":"4","key":"802_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/cpt.66","volume":"97","author":"BC Ferslew","year":"2015","unstructured":"Ferslew BC, et\u00a0al. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther. 2015;97(4):419\u201327.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"802_CR24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/liv.13362","volume":"37","author":"JD Clarke","year":"2017","unstructured":"Clarke JD, et\u00a0al. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver Int. 2017;37(7):1074\u201381.","journal-title":"Liver Int"},{"issue":"4","key":"802_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/cpt.997","volume":"104","author":"I Ali","year":"2018","unstructured":"Ali I, et\u00a0al. Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate. Clin Pharmacol Ther. 2018;104(4):749\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"802_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbt.22035","volume":"32","author":"AL Dzierlenga","year":"2018","unstructured":"Dzierlenga AL, Cherrington NJ. Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. J Biochem Mol Toxicol. 2018;32:3.","journal-title":"J Biochem Mol Toxicol"},{"issue":"5","key":"802_CR27","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cpt.1699","volume":"107","author":"A Vildhede","year":"2020","unstructured":"Vildhede A, et\u00a0al. Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease. Clin Pharmacol Ther. 2020;107(5):1128\u201337.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"802_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1124\/jpet.120.000291","volume":"376","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, et\u00a0al. Transporter activity changes in nonalcoholic steatohepatitis: assessment with plasma coproporphyrin I and III. J Pharmacol Exp Ther. 2021;376(1):29\u201339.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"802_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/138920011795016863","volume":"12","author":"M Svoboda","year":"2011","unstructured":"Svoboda M, et\u00a0al. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011;12(2):139\u201353.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"802_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, et\u00a0al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"802_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, et\u00a0al. Drug\u2013drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"802_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archinte.163.5.553","volume":"163","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne CM, et\u00a0al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553\u201364.","journal-title":"Arch Intern Med"},{"issue":"2","key":"802_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1345\/aph.1A289","volume":"36","author":"MA Omar","year":"2002","unstructured":"Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288\u201395.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"802_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1124\/dmd.105.009175","volume":"34","author":"N Ishiguro","year":"2006","unstructured":"Ishiguro N, et\u00a0al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34(7):1109\u201315.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"802_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10928-009-9139-3","volume":"36","author":"A Poirier","year":"2009","unstructured":"Poirier A, et\u00a0al. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Phar. 2009;36(6):585\u2013611.","journal-title":"J Pharmacokinet Phar"},{"issue":"1","key":"802_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/dmd.113.053819","volume":"42","author":"B Prasad","year":"2014","unstructured":"Prasad B, et\u00a0al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos. 2014;42(1):78\u201388.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"802_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/dmd.114.061580","volume":"43","author":"L Wang","year":"2015","unstructured":"Wang L, et\u00a0al. Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics. Drug Metab Dispos. 2015;43(3):367\u201374.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"802_CR38","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165(5):1260\u201387.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"802_CR39","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/hep.23103","volume":"50","author":"AT Nies","year":"2009","unstructured":"Nies AT, et\u00a0al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227\u201340.","journal-title":"Hepatology"},{"issue":"6","key":"802_CR40","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1124\/mol.51.6.913","volume":"51","author":"L Zhang","year":"1997","unstructured":"Zhang L, et\u00a0al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51(6):913\u201321.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"802_CR41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/tpj.2010.54","volume":"11","author":"G Ahlin","year":"2011","unstructured":"Ahlin G, et\u00a0al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011;11(6):400\u201311.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"802_CR42","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/bcp.12476","volume":"78","author":"SK Cho","year":"2014","unstructured":"Cho SK, et\u00a0al. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol. 2014;78(6):1426\u201332.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"802_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/clpt.2010.266","volume":"89","author":"SK Cho","year":"2011","unstructured":"Cho SK, et\u00a0al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011;89(3):416\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"802_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00424-013-1367-0","volume":"466","author":"MS Anwer","year":"2014","unstructured":"Anwer MS, Stieger B. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch. 2014;466(1):77\u201389.","journal-title":"Pflugers Arch"},{"issue":"8","key":"802_CR45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/bdd.1861","volume":"34","author":"YA Bi","year":"2013","unstructured":"Bi YA, et\u00a0al. Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin. Biopharm Drug Dispos. 2013;34(8):452\u201361.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"802_CR46","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1021\/mp400699p","volume":"11","author":"E Gozalpour","year":"2014","unstructured":"Gozalpour E, et\u00a0al. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3. Mol Pharm. 2014;11(6):1844\u201355.","journal-title":"Mol Pharm"},{"issue":"1","key":"802_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087548","volume":"9","author":"EI Lepist","year":"2014","unstructured":"Lepist EI, et\u00a0al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS ONE. 2014;9(1): e87548.","journal-title":"PLoS ONE"},{"issue":"3","key":"802_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1124\/jpet.106.102657","volume":"318","author":"MP McRae","year":"2006","unstructured":"McRae MP, et\u00a0al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther. 2006;318(3):1068\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"802_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","volume":"201","author":"B Stieger","year":"2011","unstructured":"Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol. 2011;201:205\u201359.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"802_CR50","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/hep.510290404","volume":"29","author":"J K\u00f6nig","year":"1999","unstructured":"K\u00f6nig J, et\u00a0al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 1999;29(4):1156\u201363.","journal-title":"Hepatology"},{"issue":"1","key":"802_CR51","first-page":"175","volume":"59","author":"M Kool","year":"1999","unstructured":"Kool M, et\u00a0al. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999;59(1):175\u201382.","journal-title":"Cancer Res"},{"issue":"9","key":"802_CR52","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1124\/dmd.114.057554","volume":"42","author":"BC Ferslew","year":"2014","unstructured":"Ferslew BC, et\u00a0al. Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. Drug Metab Dispos. 2014;42(9):1567\u201374.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"802_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1124\/jpet.113.207472","volume":"347","author":"ND Pfeifer","year":"2013","unstructured":"Pfeifer ND, Yang K, Brouwer KL. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther. 2013;347(3):727\u201336.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"802_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ejps.2005.12.007","volume":"27","author":"MJ Zamek-Gliszczynski","year":"2006","unstructured":"Zamek-Gliszczynski MJ, et\u00a0al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006;27(5):447\u201386.","journal-title":"Eur J Pharm Sci"},{"issue":"15","key":"802_CR55","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1021\/jm900403j","volume":"52","author":"MV Varma","year":"2009","unstructured":"Varma MV, et\u00a0al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52(15):4844\u201352.","journal-title":"J Med Chem"},{"issue":"4","key":"802_CR56","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clpt.2006.06.012","volume":"80","author":"K Yokoo","year":"2006","unstructured":"Yokoo K, et\u00a0al. Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer. Clin Pharmacol Ther. 2006;80(4):422\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"802_CR57","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/00007890-199911270-00028","volume":"68","author":"PJ Gregoor","year":"1999","unstructured":"Gregoor PJ, et\u00a0al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68(10):1603\u20136.","journal-title":"Transplantation"},{"issue":"6","key":"802_CR58","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/00007691-200112000-00020","volume":"23","author":"M Shipkova","year":"2001","unstructured":"Shipkova M, et\u00a0al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit. 2001;23(6):717\u201321.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"802_CR59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-200948050-00005","volume":"48","author":"DR Kuypers","year":"2009","unstructured":"Kuypers DR, et\u00a0al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009;48(5):329\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"802_CR60","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/FTD.0b013e318228195f","volume":"33","author":"T Fukuda","year":"2011","unstructured":"Fukuda T, et\u00a0al. Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Ther Drug Monit. 2011;33(5):658\u201362.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"802_CR61","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","volume":"23","author":"SA Kliewer","year":"2002","unstructured":"Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687\u2013702.","journal-title":"Endocr Rev"},{"issue":"2","key":"802_CR62","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1124\/jpet.104.076141","volume":"312","author":"S Teng","year":"2005","unstructured":"Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther. 2005;312(2):841\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"51","key":"802_CR63","doi-asserted-by":"publisher","first-page":"51085","DOI":"10.1074\/jbc.M308321200","volume":"278","author":"L Huang","year":"2003","unstructured":"Huang L, et\u00a0al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem. 2003;278(51):51085\u201390.","journal-title":"J Biol Chem"},{"issue":"4","key":"802_CR64","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1074\/jbc.M109326200","volume":"277","author":"HR Kast","year":"2002","unstructured":"Kast HR, et\u00a0al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277(4):2908\u201315.","journal-title":"J Biol Chem"},{"issue":"3","key":"802_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1021\/mp060010s","volume":"3","author":"G Zollner","year":"2006","unstructured":"Zollner G, et\u00a0al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006;3(3):231\u201351.","journal-title":"Mol Pharm"},{"issue":"1","key":"802_CR66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, et\u00a0al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147\u201391.","journal-title":"Physiol Rev"},{"issue":"6","key":"802_CR67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal CJ, et\u00a0al. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731\u201344.","journal-title":"Cell"},{"key":"802_CR68","volume-title":"Effect of NAFLD on regulation of hepatic transporters and metabolizing enzymes using a high fat\/high cholesterol dietary model in rat","author":"TTQ Feng","year":"2012","unstructured":"Feng TTQ. Effect of NAFLD on regulation of hepatic transporters and metabolizing enzymes using a high fat\/high cholesterol dietary model in rat. Toronto: University of Toronto; 2012."},{"issue":"4","key":"802_CR69","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/diabetes.53.4.890","volume":"53","author":"D Duran-Sandoval","year":"2004","unstructured":"Duran-Sandoval D, et\u00a0al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53(4):890\u20138.","journal-title":"Diabetes"},{"issue":"7","key":"802_CR70","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bcp.2003.12.012","volume":"67","author":"C Fang","year":"2004","unstructured":"Fang C, et\u00a0al. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol. 2004;67(7):1389\u201397.","journal-title":"Biochem Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00802-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T19:11:32Z","timestamp":1673118692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00802-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00802-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"17 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"N.O.: conceptualization, methodology, writing\u2014original draft preparation. S.Z.: writing, data collection. S.M., S.S.: validation and editing. A.H.M.: supervision and editing. F.A.: supervision and editing. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}},{"value":"No funding was used to conduct this review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}